Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totaling 4,487 shares, a drop of 25.3% from the December 31st total of 6,009 shares. Based on an average daily trading volume, of 13,077 shares, the short-interest ratio is currently 0.3 days. Approximately 0.4% of the shares of the company are sold short. Approximately 0.4% of the shares of the company are sold short. Based on an average daily trading volume, of 13,077 shares, the short-interest ratio is currently 0.3 days.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Friday, January 9th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Addex Therapeutics Price Performance

Addex Therapeutics stock opened at $7.77 on Friday. The stock’s 50 day moving average price is $7.95 and its 200 day moving average price is $8.43. Addex Therapeutics has a 1-year low of $6.51 and a 1-year high of $12.05. The company has a market cap of $9.55 million, a PE ratio of -1.35 and a beta of 1.49.

Addex Therapeutics (NASDAQ:ADXN) last released its earnings results on Thursday, December 4th. The company reported ($1.51) EPS for the quarter. The business had revenue of $0.04 million during the quarter.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.